Related by context. All words. (Click for frequent words.) 59 eplerenone 59 glatiramer acetate GA 57 CIMZIA TM 57 CsA 57 glatiramer acetate Copaxone 57 dose atorvastatin 56 TPV r 56 lumbar spine BMD 56 dalteparin 56 irbesartan 56 doxorubicin docetaxel 56 interferon beta 1a 55 bolus injection 55 relapsed MM 55 Hazard Ratio 55 PEG IFN 55 budesonide pMDI 55 APTIVUS R 55 HBeAg seroconversion 55 atorvastatin #mg 55 ezetimibe simvastatin 55 CRp 55 darunavir ritonavir 55 beta 1a 54 5-FU/LV 54 atazanavir ritonavir 54 #mg QD [002] 54 noninferiority 54 sustained virological response 54 methotrexate monotherapy 54 glatiramer acetate 54 adefovir treated 54 CCyR 54 ULORIC 54 relapsing multiple sclerosis 54 ARCOXIA 54 Acute Coronary Syndromes ACS 54 ACEI 54 complete cytogenetic response 54 iodixanol 54 mg p = 54 HBeAg negative patients 54 ACTIVE W 53 #.#/#.# mmHg [001] 53 Telintra 53 Belerofon 53 Median PFS 53 Ziprasidone 53 biochemical relapse 53 teriflunomide 53 Kinoid 53 preoperative chemotherapy 53 CR CRu 53 antiretroviral naïve 53 CR nPR 53 prednisone prednisolone plus 53 metastatic malignant 53 rFSH 52 CHAMPION PCI 52 immunomodulatory therapy 52 CALGB # [002] 52 P = .# 52 salmeterol fluticasone propionate 52 Epirubicin 52 KAPIDEX 52 DAS# remission 52 achieved ACR# 52 oxycodone CR 52 Kaplan Meier analysis 52 NSTEMI 52 Posaconazole 52 EBRT 52 prospectively defined 52 tipranavir ritonavir 52 COPAXONE 52 liver histology 52 ACTEMRA TM 52 pegylated interferon alfa 2b 52 Teriflunomide 52 STELARA 52 placebo p = 52 darunavir r 52 Fingolimod 52 dose dependently 52 recurrent GBM 52 paclitaxel carboplatin 52 Natalizumab 51 GG genotype 51 Clarithromycin 51 systemic corticosteroids 51 fibrinolytic therapy 51 androgen suppression 51 fosbretabulin 51 ACZ# 51 fludarabine cyclophosphamide 51 PANSS scores 51 cholinesterase inhibitor 51 autologous SCT 51 tipranavir r 51 adjuvant endocrine 51 antithrombotic therapy 51 DOXIL 51 clodronate 51 adriamycin 51 epoetin alpha 51 neoadjuvant treatment 51 CRu 51 Free Survival PFS 51 lumiliximab 51 Plaque Psoriasis 51 Interferon beta 1a 51 CI #.#-#.# [002] 51 administered cetrorelix 51 IOP lowering 51 PSA nadir 51 APTIVUS 51 golimumab CNTO 51 4mg/kg 51 nonsignificant difference 51 FOLFIRI alone 51 fluticasone propionate FP 51 oral FTY# 50 fluoropyrimidine 50 docetaxel pretreated 50 ug kg 50 calcium antagonist 50 medroxyprogesterone acetate 50 intratympanic 50 bile acid sequestrant 50 visilizumab 50 donepezil Aricept 50 chemoradiotherapy 50 IFN beta 50 HBeAg 50 relapsing MS 50 sargramostim 50 Bosentan 50 XELOX 50 Secondary endpoints included 50 Elitek 50 conjugated equine estrogen 50 HSCT 50 arterial thromboembolic events 50 FAMPYRA 50 Relapsing Remitting Multiple Sclerosis 50 NNT = 50 undetectable HBV DNA 50 -#.# mg dL [001] 50 radiotherapy RT 50 achieved sustained virological 50 Glatiramer acetate 50 detectable HCV RNA 50 mg BID dose 50 HandiHaler 50 MitraClip device 50 Arranon 50 ximelagatran 50 cilostazol 50 TGZ 50 ND# [002] 50 PEGylated interferon beta 1a 49 beta1 49 debulking surgery 49 PSADT 49 abacavir Ziagen 49 ATV RTV 49 inotropic 49 ADAS cog 49 intra muscular 49 BARACLUDE r 49 TURBT 49 LV dysfunction 49 IFN alfa 49 ACR# responses 49 Myelodysplastic Syndrome MDS 49 vasopressor 49 progression TTP 49 dasatinib Sprycel 49 MMSE score 49 RIGScan R 49 natalizumab 49 anthracycline containing 49 adjuvant radiotherapy 49 methacholine challenge 49 CDAI 49 pg mL 49 balsalazide 49 EDSS score 49 AST ALT 49 median PFS 49 HbA 1c levels 49 Zevalin consolidation 49 receiving VICTRELIS 49 p = .# [002] 49 Randomized Evaluation 49 RNA copies mL 49 ZACTIMA 49 mg/# mL [001] 49 secondary efficacy endpoint 49 p = NS 49 p = #.# [004] 49 patients evaluable 49 Tesmilifene 49 sipuleucel T 49 nonfatal MI 49 % CI #.#-#.# [007] 49 Unstable Angina 49 histologically confirmed 49 complete cytogenetic 49 colorectal adenoma 49 r hGH 49 univariate analysis 49 Primary endpoints 49 ADAS Cog 49 ACR# ACR# 49 hypomethylating agents 48 QVAR R 48 Decadron 48 Nebulized 48 K#R [002] 48 prespecified secondary 48 glulisine 48 external beam radiotherapy 48 PCa 48 Durezol 48 ipsilateral stroke 48 TMC# C# 48 amoxicillin clavulanate 48 plus medroxyprogesterone acetate 48 pT3 48 ACR# response 48 EBMT criteria 48 periprocedural 48 Partial Response 48 NMIBC 48 postintervention 48 multicentre randomized 48 CI -#.# 48 binary restenosis 48 bortezomib refractory 48 Biogen Avonex 48 viral kinetics 48 Adjuvant chemotherapy 48 microg 48 Score DAS# 48 posttreatment 48 CALGB 48 Zyclara 48 FOCALIN XR 48 Newly Diagnosed Multiple Myeloma 48 Central Venous Catheter 48 β blockers 48 methylprednisolone 48 stavudine d4T 48 Melphalan 48 % Confidence Interval 48 evaluable 48 pharmacokinetics PK 48 mg clopidogrel 48 reinfarction 48 evaluable subjects 48 Etanercept 48 % CI #.#-#.# [003] 48 paroxysmal atrial fibrillation 48 NYHA functional class 48 lymphocyte count 48 conjugated equine estrogens 48 plasma renin activity 48 OZG 48 cells mcL 48 cisplatin chemotherapy 48 idraparinux 48 ß blockers 48 Index CDAI 48 mL kg 48 COZAAR 48 relapsed CLL 48 cefotaxime 48 clinically meaningful improvement 48 radical prostatectomy RP 48 advanced hepatocellular carcinoma 48 Zentase 48 HAQ DI 48 prostate cancer CaP 48 completely resected 48 de novo AML 48 HBsAg 48 FluCAM arm 48 IPSS 47 pharmacodynamic PD 47 short acting bronchodilator 47 oblimersen 47 CZP 47 fingolimod 47 anagrelide 47 etoposide 47 -#.# ± [002] 47 EGFR mutation positive 47 p = #.# [003] 47 interferon beta 47 AVADO 47 ara C 47 statistically significant p = 47 azacytidine 47 nondiabetic patients 47 CLL SLL 47 pg ml 47 ACOMPLIA R 47 LVEF 47 nadroparin 47 cyclophosphamide methotrexate 47 gm dl 47 Xanafide 47 TNF α 47 % CI #.#-#.# [008] 47 achieved CCyR 47 placebo p 47 Brief Psychiatric 47 pyrazinamide 47 SWOG 47 CI #.#-#.# p = 47 RRMS 47 GW# [003] 47 AA Amyloidosis 47 nonsignificant 47 DAS# CRP 47 p = .# [001] 47 OvaRex MAb 47 ER CHOP 47 See #Z [002] 47 multivariate Cox 47 bivalirudin alone 47 beta interferons 47 β blocker 47 Campath alemtuzumab 47 HCQ 47 pT2 47 drotrecogin alfa activated 47 REVIVE Diabetes 47 Waldenstrom Macroglobulinemia 47 oral diclofenac 47 BH AR End 47 PCWP 47 exemestane 47 ertapenem 47 ErbB2 positive 47 achieving PASI 47 SIMPADICO 47 serologically active patients 47 % CI #.#-#.# [006] 47 adverse cytogenetics 47 caspase inhibitor 47 = #.#-#.# 47 SJIA 47 pain palliation 47 metastatic malignant melanoma 47 AVONEX ® 47 biochemical recurrence 47 verapamil 47 Cinacalcet HCl 47 saline placebo 47 Median progression 47 locoregional disease 47 % CI #.#-#.# [001] 47 prospectively stratified 47 ONTARGET 47 GSK# [001] 46 FOLFIRINOX 46 tamoxifen Nolvadex ® 46 -#.# mg dL [002] 46 HGPIN 46 μg d 46 Hb A1C 46 iPTH 46 APEX AMI 46 BPH LUTS 46 R0 resection 46 confidence interval #.#-#.# 46 IFN γ 46 receptor antagonism 46 remission CR 46 ACR# [002] 46 CYPHER ® 46 Cardiotoxicity 46 Kaplan Meier estimates 46 DAS# scores 46 bivalirudin monotherapy 46 corifollitropin alfa 46 ug dose 46 mineralocorticoid receptor 46 ratio ICER 46 thyroglobulin 46 NNRTI resistance 46 Kogenate ® FS 46 UPDRS scores 46 ALT elevation 46 advanced adenoma 46 Rate ORR 46 clomiphene citrate 46 medroxyprogesterone acetate MPA 46 mITT population 46 TT genotype 46 call ORQ 46 serum concentrations 46 AIM HIGH 46 nonrandomized 46 mCRPC 46 MADRS score 46 microgram mcg 46 nonmetastatic prostate cancer 46 TAXUS V 46 % CI #.#-#.# [005] 46 interquartile range 46 hematologic toxicity 46 HCV antibody 46 endothelin antagonists 46 oocytes retrieved 46 RECIST criteria 46 NIH CPSI 46 undetectable HCV RNA 46 preoperative PSA 46 isoproterenol 46 μg mL 46 mmol kg 46 tHcy 46 SSc 46 TAXUS ATLAS 46 COPERNICUS 46 VT VF 46 haematologic 46 -#.# log# 46 confidence interval CI 46 NIHSS 46 primary percutaneous coronary 46 atherosclerotic renal artery stenosis 46 Stage IIIb 46 thrombus aspiration 46 ON #.Na 46 talabostat 46 NPM1 mutation 45 DEB# 45 basal cell carcinoma BCC 45 PANSS 45 selective antagonist 45 NTx 45 RE LY ® 45 patientswith 45 achieve sustained virological 45 Thrombolysis 45 ADCS CGIC 45 metered dose inhaler MDI 45 PsA ulcerative colitis 45 ISOCOUNTRY3 45 CIN2 + 45 p = #.# [002] 45 euthyroid 45 PsA 45 QTcF 45 Intravenous immunoglobulin 45 POL PRO 45 MIs 45 CI #.#-#.# [001] 45 ENGAGE AF TIMI 45 HOMA IR 45 serum biomarker 45 sleeve lobectomy 45 mL/min/#.# m 2 45 liver transplant recipients 45 effector function 45 LV ejection fraction 45 HDRS 45 exacerbations 45 hormone receptor negative 45 Afib 45 K ras mutations 45 Troj Bancban 45 albumin excretion rate 45 mL/min/#.# m2 45 diabetic gastroparesis 45 multivariate adjustment 45 hematologic abnormalities 45 Interferon beta 45 recurrent DVT 45 Corticosteroid 45 UPDRS motor 45 nonvertebral fracture 45 PROCHYMAL 45 Phase IIA 45 relapsing remitting multiple sclerosis 45 Ovidrel 45 PRIALT 45 Relapsing remitting 45 evaluating Actimmune 45 Omacetaxine 45 creatinine ratio 45 SSRI SNRI 45 EORTC 45 Anas Younes MD 45 PTI MIJ 45 ORACLE MS 45 â ‰ ¥ 45 baseline FEV 45 VFQ 45 Multiple Myeloma MM 45 psoriatic arthritis PsA 45 DTIC 45 sd = 45 XmAb# 45 RU EUROPE EEU EMRG 45 CORD II 45 VGPR 45 vasoactive 45 Montgomery Åsberg Depression 45 myocardial infarction stroke 45 NSABP B 45 multivariate analyzes 45 ANCOVA 45 Adrenomyeloneuropathy AMN 45 Fenretinide 45 Pain Rating Scale 45 Prognostic Index 45 p = ns 45 statistical significance p 45 MADRS 45 Stenting Trial 45 hc2 45 pCR 45 MDD 45 Relapsing remitting MS 45 Avonex interferon beta 1a 45 lung fibrosis 45 invasive carcinomas 45 cytoreductive nephrectomy 45 -#.# mmol L 45 neuropathy sensory 45 DAS# [002] 45 coxib 45 RTOG 45 relapsing remitting MS 44 HLA DR4 44 cytogenetic abnormalities 44 ATL/TV# 44 ECOG PS 44 thrombopoietin 44 radical cystectomy 44 IL#B 44 Biogen Idec Elan 44 uM 44 CC genotype 44 p = 44 Platelet counts 44 PEY 44 μg ml 44 urine albumin 44 tazobactam 44 PTI CORR 44 statistically significant p 44 beta interferon 44 subscale scores 44 microbiologically evaluable 44 prospectively randomized 44 Kahalalide F 44 BCIRG 44 K#N 44 del 5q 44 SPECT MPI 44 1α 44 LPS induced 44 μmol L 44 carotid IMT 44 Novantrone 44 IMRIS TSX 44 thrombocytopenic 44 CNS LS 44 amphetamine methamphetamine 44 LAB CGRP 44 interferon alpha IFN alpha 44 enzyme inhibition 44 p ≤ 44 TQT 44 Kaplan Meier 44 CTEPH 44 UNLOAD 44 Androgel R 44 mmHg p = 44 oral treprostinil 44 Fibromyalgia syndrome 44 PTI SJY 44 IFN Beta CTP 44 CIBIC plus 44 TIMP 1 44 Daclizumab 44 IPTp 44 transrectal ultrasound guided 44 Acute Myeloid Leukaemia AML 44 Cardiopulmonary bypass 44 CIPN 44 haematological toxicity 44 Viread Emtriva SUSTIVA 44 SF #v# 44 macrophage inflammatory protein 44 advanced adenomas 44 CAMMS# 44 ICD shocks 44 Secondary endpoints include 44 Valproic acid 44 Pneumocystis carinii pneumonia 44 NFV 44 bioavailable testosterone 44 nonischemic 44 HIV uninfected 44 Xalatan R 44 See CLINICAL PHARMACOLOGY 44 mediated inhibition 44 FACEOFFS 44 rapid virological response 44 Phase III randomized controlled 44 mesilate 44 MGUS 44 Carotid Artery Stenting 44 phenelzine 44 SNP rs# [002] 44 EchoCRT 44 MC# [001] 44 squamous intraepithelial lesions 44 % CI #.#-#.# [002] 44 bronchioloalveolar carcinoma 44 RECIST Response Evaluation Criteria 44 n = 44 relapsing remitting 44 symptomatic intracranial hemorrhage 44 ACTH 43 serum alkaline phosphatase 43 multivariable analysis 43 preintervention 43 EUROPE ASIA EEU EMRG 43 Alzheimer Disease Assessment 43 polyarticular 43 IFN alpha 2b 43 Complete Response CR 43 TIM McMANUS 43 advanced pancreatic neuroendocrine 43 inducible nitric oxide synthase 43 Monocyte 43 betamethasone 43 Sinemet 43 mmHg diastolic 43 pretransplant 43 PENNVAX B 43 seronegative 43 Scale CNS 43 INGRAM MICRO 43 CAARS 43 mTSS 43 NDA resubmission 43 antituberculosis 43 BMS p = 43 PCI percutaneous coronary 43 hip resurfacing arthroplasty 43 TASKi3 43 OZURDEX 43 TLR antagonist 43 FSAD 43 mean baseline HbA1c 43 Pyratine XR TM 43 idiopathic Parkinson disease 43 simvastatin #mg 43 Antiviral Therapy 43 lymphocytosis 43 ClearWay TM 43 Forteo ® 43 sustained ventricular tachycardia 43 Myelofibrosis 43 pmol L 43 NNRTI resistant virus 43 renal allograft 43 histologically proven 43 oral moxifloxacin 43 recurrent ischemic 43 ELISPOT 43 pulmonary exacerbations 43 Hydrochloride 43 ng dl 43 Postmenopausal hormone therapy 43 RASSF1A 43 intima media thickness 43 Stenting Trial CREST 43 stable angina 43 NRTI sparing 43 intraperitoneally 43 Secondary efficacy endpoints 43 Medication adherence 43 demyelinating 43 recurrent glioblastoma 43 angiotensin converting enzyme 43 TrkB 43 induces antibodies 43 Alemtuzumab 43 Persistent Sleep 43 aMCI precursor 43 Biogen Idec Avonex 43 anticholinergic medication 43 FLOMAX 43 BUPHENYL R 43 EndoTAGTM 1 43 mRS 43 JMR Sunnex 43 recurrent VTE 43 diameter stenosis 43 univariate analyzes 43 Chronic Sinusitis 43 CGRP 43 FDG PET scan 43 systemic embolism 43 ANTEGREN 43 thromboembolism 43 hematological malignancy 43 heterozygotes 43 estimated GFR 43 rs# [004] 43 T1c 43 VKORC1 43 detrusor overactivity 43 abnormal cytology 43 glucocorticoid induced 43 Geographic Atrophy 43 Rating Scale BPRS 43 spontaneous bacterial peritonitis 43 Betaferon Betaseron 43 transferases 43 FACIT Fatigue 43 Carotid Revascularization Endarterectomy vs. 43 insulin sensitization 43 QRS duration 43 pretreatment serum 43 elevated transaminases 43 Extavia 43 granted Orphan Designation 43 statistically significant predictor 43 subscore 43 Timed Walk 43 sensory neuropathy 43 HLA A2 43 Follistim 43 Cefazolin 43 Operative mortality 43 radical nephrectomy 42 randomized multicenter 42 SGRQ 42 trimethoprim 42 Temodar ® 42 AUCs 42 glycated albumin 42 diabetes mellitus DM 42 idiopathic membranous nephropathy 42 IIIb 42 CRRN 42 PITX2 methylation 42 lutropin alfa 42 CDK inhibitor 42 Fracture Intervention Trial 42 ± SD 42 dyspnoea 42 ischemia driven 42 Sunitinib malate 42 IXJ 42 SEASONALE 42 seropositivity 42 prostatic adenocarcinoma 42 sodium nitroprusside 42 Disease Activity 42 MBq 42 HGD 42 mITT 42 ACR Pedi 42 FSH CTP 42 ETDRS 42 Yentreve ® 42 Soft Tissue Sarcoma 42 P selectin 42 echocardiographic parameters 42 contralateral prophylactic mastectomy 42 immune thrombocytopenic purpura 42 VIDAS 42 polyp recurrence 42 x ULN 42 GFAP 42 DAC HYP 42 Megace ® 42 PHASE III 42 alpha hydroxyprogesterone caproate 42 AERIUS 42 mg ml 42 HF hospitalization 42 anticholinergic agents 42 progressive demyelinating disease 42 ERBB2 42 immunostaining 42 lymphadenectomy 42 tPSA 42 diabetic kidney 42 clinicopathological features 42 JOE 'S RESTAURANT 42 ECLS 42 UACR 42 DLQI 42 Comorbidity 42 EÖ 42 UPDRS 42 warfarin sodium 42 nucleotide analog 42 Weinstock Guttman 42 bendroflumethiazide 42 nonfatal stroke 42 visit www.conservation.org 42 natriuretic peptide 42 ≥ 42 Idiopathic Pulmonary Fibrosis 42 cyanocobalamin 42 somatostatin 42 treat relapsing forms 42 EQ 5D 42 Chronic HCV 42 CD8 responses 42 WOMAC pain 42 metronidazole gel 42 EMRG VIO 42 MBP# dirucotide 42 torsade de pointes 42 Pregabalin 42 prospective randomized controlled 42 regression coefficient 42 nonfatal myocardial infarction 42 recurrent venous thromboembolism 42 CORE OM 42 Resynchronization 42 adrenergic agonists 42 treat NNT 42 lymphoproliferative disorders 42 Bovi Shield GOLD 42 ethinyl estradiol tablets 42 ^ sup #m 42 2 microglobulin 42 coronary stenosis 42 ATTAIN 42 iPrEx study 42 RENAL 42 Pharmacodynamic 42 Unified Parkinson Disease 42 oral contraceptive OC 42 Oncotype 42 Hsp# inhibitor STA 42 tegafur 42 alemtuzumab Campath 42 Oral Compound 42 CAPRIE 42 Expedited Review 42 underwent resection 42 Subscale 42 mIU ml 42 Progressive Multifocal Leukoencephalopathy 42 undergoing Percutaneous Coronary 42 pDC 42 cervical carcinoma 42 angiographically 42 bone scintigraphy 42 elective percutaneous coronary 41 Acute Promyelocytic Leukemia 41 intact parathyroid hormone 41 cutaneous melanoma 41 Hazard Ratio = 41 Pain Intensity 41 Adrenergic 41 noncardiovascular mortality 41 comorbid anxiety 41 GH deficiency 41 Evaluable 41 peri procedural 41 transthoracic 41 Myelodysplastic Syndrome 41 myocardial revascularization 41 HBV infected 41 portal vein thrombosis 41 xenograft model 41 ASSERT 41 Psoriasis Area 41 ^ Tc 41 #β 41 COR Analyzer 41 Rebif interferon beta 1a 41 radical retropubic prostatectomy 41 Bipolar Depression 41 heterozygous FH 41 Systemic Lupus Erythematosus SLE 41 P ≤ 41 dyssynchrony 41 CI = 41 1mg 41 SELENA SLEDAI 41 F FDG PET 41 aged ≥ 41 HPLC MS 41 adjuvant systemic 41 interleukin IL 41 FACIT 41 TOUCH Prescribing Program 41 mean baseline A1C 41 nmol 41 ‰ ¥ 41 EMRG POL 41 ALLHAT 41 β2 41 COMT genotype 41 MEMS ICs 41 neutralizing antibody 41 ECOG 41 NSABP 41 Multicenter Automatic Defibrillator Implantation 41 PrA 41 Jamie Random Musings 41 functional mitral regurgitation 41 Stent p = 41 L methionine 41 EMRG 41 See #Z [001] 41 CARE HF 41 NIHSS score 41 #F FDG 41 Angioedema 41 nanomolar range 41 phosphodiesterase inhibitors 41 ejection fractions 41 Tubulin 41 PaO 2 41 Sorafenib HCC Assessment 41 Lp PLA 2 41 PAOD 41 multivariable adjusted 41 Clinically Isolated Syndrome 41 MRgFUS 41 Adult Cardiac Surgery 41 resected pancreatic cancer 41 growth hormone secretagogue 41 WL OTL 41 thiopurine 41 atrial natriuretic peptide 41 Gliclazide 41 8mg 41 ORAL Solo 41 Btk Inhibitor 41 Gazeta Wyborcza pp. 41 uremic pruritus 41 MAINTAINS BUY 41 untreated CLL 41 seminal vesicle invasion 41 Copaxone 41 Kruskal Wallis test 41 SGS# 41 t# c# CLA 41 erection hardness 41 mIU L 41 Paromomycin IM Injection 41 PLCO 41 Angiotensin converting enzyme 41 Rating Scale UPDRS 41 Q TOF LC 41 mU liter 41 ACh 41 By JENNIFER LEARN 41 Diabetic Foot Ulcer 41 RSY 41 mU 41 IABP 41 α tocopherol 41 randomized Phase III 41 Natazia 41 advanced neoplasia 41 ovarian cancer biomarker 41 Ocular Surface Disease 41 RICE BRAN Rs 41 Sibutramine Cardiovascular Outcomes 41 ARESTIN ® 41 procainamide 41 Etf Un TSX 41 Novartis Gilenia 41 active PsA 41 evaluating carfilzomib 41 GBX1 #.# [001] 41 BEXXAR Therapeutic Regimen 41 ionophore 41 Multicenter 41 nephron sparing surgery 41 thymidine kinase 41 PIX# [002] 41 CFQ R 40 immunized mice 40 adrenergic receptor agonists 40 IgA antibody 40 Reperfusion